Abstract:Abstract Background Hemorrhagic transformation (HT) is a common complication of delayed tissue plasminogen activator (t-PA) treatment for ischemic stroke. Peroxynitrite plays an important role in the breakdown of blood–brain barrier (BBB) and the development of HT. We tested the hypothesis that Angong Niuhuang Wan (AGNHW), a traditional Chinese medicinal formula, could be used in conjunction with t-PA to protect the BBB, minimize HT, and improve neurological function by suppressing peroxynitrite-mediated matrix metalloproteinase-9 (MMP-9) activation. Methods We first performed quality control study and chemical identification of AGNHW by using UPLC. In animal experiments, male Sprague–Dawley rats were subjected to 5 h of middle cerebral artery occlusion (MCAO) followed by 19 h of reperfusion plus t-PA infusion (10 mg/kg) at 5 h of cerebral ischemia. AGNHW (257 mg/kg) was given orally at 2 h after MCAO. Hemorrhagic transformation was measured using hemorrhagic scores and hemoglobin levels in ischemic brains. Evans blue leakage was utilized to assess the severity of the blood–brain barrier (BBB) damage. The modified neurologic severity score (mNSS) test was used to assess neurological functions. Peroxynitrite and superoxide was detected by using fluorescent probes. MMP-9 activity and expression were examined by gelatin zymography and immunostaining. The antioxidant effects were also studied by using brain microvascular endothelial b.End3 cells exposed to 5 h of oxygen and glucose deprivation (OGD) plus 5 h of reoxygenation with t-PA treatment (20 μg/ml). Results AGNHW significantly reduced the BBB damage, brain edema, reduced hemorrhagic transformation, enhanced neurological function, and reduced mortality rate in the ischemic stroke rats with t-PA treatment. AGNHW reduced peroxynitrite and superoxide in vivo and in vitro and six active chemical compounds were identified from AGNHW with peroxynitrite scavenging activity. Furthermore, AGNHW inhibited MMP-9 activity, and preserved tight junction protein claudin-5 and collagen IV in the ischemic brains. Conclusion AGNHW could be a potential adjuvant therapy with t-PA to protect the BBB integrity, reduce HT, and improve therapeutic outcome in ischemic stroke treatment via inhibiting peroxynitrite-mediated MMP-9 activation. Graphical Abstract

Rosiglitazone Attenuates Hyperglycemia-Enhanced Hemorrhagic Transformation after Transient Focal Ischemia in Rats.

Effects of Rosiglitazone on Serum Levels of Lipids and Inflammatory Factors in Atherosclerotic Rats

Rosiglitazone Via Upregulation of Akt/Enos Pathways Attenuates Dysfunction of Endothelial Progenitor Cells, Induced by Advanced Glycation End Products

Rosiglitazone ameliorates the dysfunction of endothelial progenitor cells induced by advanced glycation end products

Rosiglitazone attenuates early brain injury after experimental subarachnoid hemorrhage in rats

Cardioprotective effects of acute rosiglitazone treatment

Rosiglitazone attenuates endothelial progenitor cell apoptosis induced by TNF-α via ERK/MAPK and NF-κB signal pathways.

Angong Niuhuang Wan reduces hemorrhagic transformation and mortality in ischemic stroke rats with delayed thrombolysis: involvement of peroxynitrite-mediated MMP-9 activation

Suppression of Hypoxia-Inducible Factor-1Alpha and Its Downstream Genes Reduces Acute Hyperglycemia-Enhanced Hemorrhagic Transformation in a Rat Model of Cerebral Ischemia.

Rosiglitazone Attenuates Endothelin-1–Induced Vasoconstriction by Upregulating Endothelial Expression of Endothelin B Receptor

Rosiglitazone Promotes White Matter Integrity And Long-Term Functional Recovery After Focal Cerebral Ischemia

Rosiglitazone Attenuated Endothelin‐1‐induced Vasoconstriction of Pulmonary Arteries in the Rat Model of Pulmonary Arterial Hypertension (1089.13)

Rosiglitazone Attenuated Endothelin-1-Induced Vasoconstriction of Pulmonary Arteries in the Rat Model of Pulmonary Arterial Hypertension Via Differential Regulation of ET-1 Receptors

Rosiglitazone attenuates hypoxia-induced renal cell apoptosis by inhibiting NF-κB signaling pathway in a PPARγ-dependent manner

Peroxisome Proliferator–activated Receptor-Γ Agonist Rosiglitazone Reduces Clinical Inflammatory Responses in Type 2 Diabetes with Coronary Artery Disease after Coronary Angioplasty

Rosiglitazone attenuates renal injury in diabetic rats via inhibiting over-expression of matrix metalloproteinase-9 in the kidney

Rosiglitazone Prevents Renal Injury Through an Anti-inflammatory Mechanism in STZ-induced Diabetic Rats

Effect of Pioglitazone on Expression of Hypoxia-Inducible Factor 1α and Vascular Endothelial Growth Factor in Ischemic Hindlimb of Diabetic Rats.

Intra-hematoma Rosiglitazone infusion therapy attenuates blood-brain barrier disruption after intracerebral hemorrhage in rabbits

Rosiglitazone Protects Diabetic Rats Against Kidney Injury Through the Suppression of Renal Matrix Metalloproteinase-9 Expression

Rosiglitazone protects diabetic rats against kidney disease through the suppression of renal moncyte chemoattractant protein-1 expression